Since the opening of the 18th National Congress of CPC, technical innovation has become one of the core governance concepts of the  Central Committee; “Innovation-driven” has become the key development strategy for China.

　　——an excerpt from Guangming Daily on Oct 9th, 2017　

Innovation-driven Development Strategy fueled businesses in China. As the strategy of technical innovation has been pushed forward over the last five years, Hansoh Pharma, one of Lianyungang’s representative enterprise in the innovative pharmaceutical industry, has made remarkable achievements in attracting high-end talents, developing key products and marketing innovative drugs globally, demonstrating our city’s significant progress in the innovative pharmaceutical industry since the opening of the 18th national congress.

Step up Transformation: Transition from “Combination of Imitation and Innovation” to “Independent Innovation”

In May 2014, the successful launch of Hansoh Pharma’s Category1.1 innovative drug Mailingda (morinidazole sodium chloride injection) after 10 years of development signals a key step during the Company’s transitioning from “combination of imitation and innovation” to “independent innovation”.  

Hansoh Pharma has never strayed away from the fundamental strategy of innovation-driven development. The company has invested highly in R&D to promote continuous upgrading and perfection of the R&D system over years, which is also the development trend of the world’s pharmaceutical industry over the last five years and the strategic requirement of developing our nation’s pharmaceutical industry.  

The company has R&D centers in Lianyuangang, Zhangjiang of Shanghai , constituting a complete pharmaceutical research and development system covering preclinical research, clinical trial, registration and filing. The company boasts more than 10 R&D platforms such as National Technical Center, National Post-doctoral Research Station, National and Local Joint Center for Long-acting Polypeptide Drugs, Jiangsu Academician Workstation, Jiangsu Alimentary Canal Pharmaceutical Engineering Technology Research Center, and Key Laboratory of Bio-drugs in Jiangsu Province, and has established long-term cooperation with multiple domestic scientific research institutes.   

Technical innovation provides Hansoh with strong competiveness. Its CNS drugs are ranked No.1 while oncology drugs ranked Top 4 in terms of market shares. Flagship products including CNS drug Oulanning (Olanzapine Tablets), oncology drugs Zefei (Gemcitabine Hydrochloride for Injection), Pulaile (Pemetrexed Disodium for Injection), and diabetes drug Fulaidi (Repaglinide Tablets) have successively become market leaders among peers.

Hansoh has accumulatively undertaken over 60 national and provincial technical research projects, with 20 key national programs in new drug invention and 400 patent applications filed domestically and globally. The development and application programs of flagship products Zefei and Oulanning were respectively awarded the Advancement of Science and Technology Award by the State Council. Currently the company has nearly 20 innovative drugs at varied R&D stages, enabling it to realize leapfrog development in the next few years.

Leapfrog Development: from Global Market to Global Research

With its steady growth, Hansoh started aiming at the global market. Relying on its vigorous innovation mechanism, the company actively followed national strategies of “Healthy China 2030” and “Made in China 2025”. Since the 18th National Congress, the company has launched multiple new drugs into the mainstream markets in Europe and U.S. while realized simultaneous development of innovative drugs around the globe.   

Hansoh’s successful entrance into the global market can be attributed to its advanced quality management philosophy, strict QC system and continuous infrastructure investment. Adhering to the Quality-by-Design quality management concept, the company has set up a whole life cycle QC system, built an EU-standard pharmaceutical industrial park, and introduced world-class production facilities.

Since the 18th National Congress, Hansoh Pharma has exported into the mainstream markets in Europe and America while increasing APIs export: in 2013, the company’s products Zefei and Gainuo (lyophilized powder injection) were launched in the US, and three years later, oncology drug Pulaile was approved by Japanese PMDA. In addition, Hansoh was one of the first pharma companies that successfully launched pharmaceutical products in Russia, Southeast Asia and the Middle East, etc. Now the Company has 6 pharmaceutical products and 8 APIs available in 30 countries and regions all over the world. Hansoh was honored as “Leading Enterprise in the Internationalization of Pharmaceuticals” as recognition of its market-leading position in this regard

While its international sales are rapidly growing, the Company is also increasing its global footprint of research. There are innovative drugs under multi-center clinical trials across countries and regions. From global distribution to global trials, Hanson’s globalization initiative is sure to bring about new drivers for growth

Standing at the intersection of past and future, Hansoh Pharma will carry on the mission of “serving the society and building a healthy world”, focus on technical innovation and globalization, closely follow the national strategies of “Healthy China 2030” and “Made in China 2025” in order to realize leapfrog development and contribute to the building of New Jiangsu and fast growth of local economy.